Superior response and survival of intensive chemotherapy over venetoclax plus azacitidine in newly diagnosed KIT-mutated acute myeloid leukemia

Abstract Although KIT mutations hold significant prognostic value in acute myeloid leukemia (AML), their impact on selecting first-line treatment remains unclear. This retrospective study of 222 newly diagnosed AML patients therefore compared the efficacy of venetoclax plus azacitidine (VA) versus i...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Qingli Ji, Xinwen Jiang, Xiaoqing Li, Chen Cao, Xinrui Zhang, Minran Zhou, Sai Ma, Chunyan Chen
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Springer 2026-02-01
Colecção:	Annals of Hematology
Assuntos:	Acute myeloid leukemia KIT Intensive chemotherapy Venetoclax
Acesso em linha:	https://doi.org/10.1007/s00277-026-06841-4
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!